News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
701,442 Results
Type
Article (43567)
Company Profile (363)
Press Release (657512)
Section
Business (207545)
Career Advice (2004)
Deals (35885)
Drug Delivery (98)
Drug Development (83683)
Employer Resources (170)
FDA (16567)
Job Trends (15058)
News (351894)
Policy (33169)
Tag
Academia (2662)
Alliances (50387)
Alzheimer's disease (1272)
Approvals (16471)
Artificial intelligence (129)
Bankruptcy (356)
Best Places to Work (11694)
Biotechnology (261)
Breast cancer (117)
Cancer (1014)
Cardiovascular disease (88)
Career advice (1672)
Cell therapy (241)
Clinical research (66101)
Collaboration (357)
Compensation (176)
COVID-19 (2605)
C-suite (88)
Data (919)
Diabetes (148)
Diagnostics (6232)
Drug pricing (84)
Earnings (85258)
Employer resources (148)
Events (111959)
Executive appointments (260)
FDA (17032)
Funding (313)
Gene therapy (176)
GLP-1 (618)
Government (4434)
Healthcare (19165)
Infectious disease (2683)
Inflammatory bowel disease (110)
Interviews (310)
IPO (16508)
Job creations (3688)
Job search strategy (1427)
Layoffs (437)
Legal (7948)
Lung cancer (168)
Manufacturing (167)
Medical device (13389)
Medtech (13394)
Mergers & acquisitions (19410)
Metabolic disorders (406)
Neuroscience (1528)
NextGen Class of 2024 (6704)
Non-profit (4563)
Northern California (1284)
Obesity (239)
Opinion (193)
Patents (99)
People (57207)
Phase I (20557)
Phase II (29063)
Phase III (21736)
Pipeline (260)
Postmarket research (2710)
Preclinical (8774)
Radiopharmaceuticals (250)
Rare diseases (206)
Real estate (5994)
Regulatory (22045)
Research institute (2416)
Resumes & cover letters (352)
Southern California (1147)
Startups (3694)
United States (12437)
Vaccines (569)
Weight loss (187)
Date
Today (252)
Last 7 days (968)
Last 30 days (3290)
Last 365 days (36655)
2024 (31901)
2023 (41052)
2022 (52299)
2021 (56830)
2020 (55104)
2019 (47639)
2018 (35959)
2017 (33040)
2016 (32445)
2015 (38453)
2014 (32166)
2013 (27179)
2012 (29335)
2011 (30046)
2010 (28197)
Location
Africa (741)
Arizona (192)
Asia (38381)
Australia (6344)
California (2934)
Canada (1206)
China (224)
Colorado (131)
Connecticut (130)
Europe (84280)
Florida (420)
Georgia (109)
Illinois (328)
Indiana (188)
Kansas (98)
Maryland (547)
Massachusetts (2432)
Michigan (144)
Minnesota (257)
New Jersey (868)
New York (876)
North Carolina (729)
Northern California (1284)
Ohio (132)
Pennsylvania (783)
South America (1116)
Southern California (1147)
Texas (410)
Washington State (338)
701,442 Results for "chimeric therapies inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Interius BioTherapeutics Doses First Patient with in vivo Chimeric Antigen Receptor (CAR) Gene Therapy for B-cell Malignancies
October 23, 2024
·
3 min read
CHIMERIC THERAPEUTICS ANNOUNCES FDA CLEARANCE OF IND APPLICATION FOR CHM 2101, A NOVEL CDH17 CAR T CELL THERAPY FOR ADVANCED GASTROINTESTINAL CANCERS
Chimeric Therapeutics (ASX:CHM, “Chimeric” or the “Company”), an Australian leader in cell therapy, announced today that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application of CHM 2101, Chimeric’s first in class CDH17 CAR T cell therapy for gastrointestinal cancers.
October 31, 2023
·
4 min read
Biotech Bay
Kyverna Therapeutics and National Institutes of Health Co-Author Seminal Review on Cell Therapy for Autoimmunity in Nature Reviews Immunology
Kyverna Therapeutics, Inc. announced the publication in Nature Reviews Immunology of a manuscript co-authored with the National Institutes of Health titled “Chimeric antigen receptor T cell therapy for autoimmune disease”.
June 10, 2024
·
5 min read
Press Releases
PeproMene Bio announced study demonstrating strong polyfunctionality of novel chimeric antigen receptor (CAR) T cells
August 8, 2024
·
4 min read
Press Releases
Capstan Therapeutics to Present Preclinical Data on Lead In Vivo Chimeric Antigen Receptor (CAR)-T Candidate, CPTX2309, at American College of Rheumatology (ACR) Convergence 2024
September 27, 2024
·
3 min read
Press Releases
B-Cell Non-Hodgkin Lymphoma Market to Reach a CAGR of 5.83% during 2024-2034, Impelled by Chimeric Antigen Receptor T-Cell (CAR-T) Therapy
July 22, 2024
·
11 min read
Pharm Country
BioRestorative Therapies, Inc. to attend the Jefferies 2024 Healthcare Conference
BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies, today announced that CEO Lance Alstodt will participate at the Jefferies Global Healthcare Conference being held June 5-6, 2024 at the Marriot Marquis in New York.
June 4, 2024
·
3 min read
Drug Development
City of Hope-developed Chimeric Antigen Receptor (CAR) T Cell Therapy Shows Clinical Activity in Patients With Aggressive Brain Tumors in a Phase 1 Trial
A pioneering Phase 1 CAR T cell therapy trial for the treatment of glioblastoma at City of Hope, one of the largest cancer treatment and research organizations in the United States, demonstrates promising clinical activity against incurable brain tumors, according to research published in Nature Medicine.
March 7, 2024
·
8 min read
Pharm Country
Celularity Data Published in Journal for ImmunoTherapy of Cancer Reveals Benefits of Placental Circulating T Cells for CAR-T Therapy
Celularity Inc. announced that the Journal for ImmunoTherapy of Cancer, a peer-reviewed online journal of the Society for Immunotherapy of Cancer, published data highlighting the potential advantages of Celularity’s T-Cell platform for future immunotherapies including chimeric antigen receptor therapies.
May 14, 2024
·
5 min read
Drug Development
Atara Biotherapeutics Presents Preclinical Data on ATA3219, an Allogeneic CD19-Targeted CAR T Therapy for the Treatment of B-Cell Driven Autoimmune Diseases, at the ISCT 2024 Annual Meeting
Atara Biotherapeutics, Inc. (Nasdaq: ATRA) today announced preclinical data supporting the potential of ATA3219, an allogeneic, anti-CD19 chimeric antigen receptor (CAR) T-cell therapy candidate for the treatment of B-cell driven autoimmune diseases.
May 29, 2024
·
8 min read
1 of 70,145
Next
